Tisagenlecleux-B (Tisavance)
Product detail for Tisagenlecleux-B, INN: tisagenlecleux beta. Therapeutic area: Haematology. This record shows all linked substances, markets, applications, presentations, and labeling artefacts.
Product ID
PROD-025
INN
tisagenlecleux beta
Therapeutic Area
Haematology
Status
Pending
Owner
Priya Sharma
Created
2022-03-02
Last Updated
2023-07-15
Markets
6
Presentations
| Form | Strength | Route |
|---|---|---|
| Ophthalmic solution | 1 mg/mL | Transdermal |
| Film-coated tablet | 10 mg/mL | Inhalation |
| Ophthalmic solution | 50 mg | Transdermal |
| Concentrate for solution for infusion | 2.5 mg | Subcutaneous |
Active Substances
| ID | Name | INN | CAS | Type | Status |
|---|---|---|---|---|---|
| SUB-022 | Sacubitrivex | sacubitrivex | 54693-87-2 | small-molecule | Active |
| SUB-030 | Mavacamtamex | mavacamtamex | 81169-60-9 | small-molecule | Pending |
Applications (3)
| Application # | Market | Procedure Type | Status | Owner | Submitted |
|---|---|---|---|---|---|
| ANVISA-2020-0025 | Poland | MAA | Completed | James O'Brien | 2024-04-05 |
| ANMAT-2020-0055 | Poland | Label Update | Draft | Tomoko Ikeda | 2023-04-09 |
| ANVISA-2020-0085 | Poland | sNDA | Failed | Tomoko Ikeda | 2022-05-13 |